|
🐜
|
Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial.
10 auth.
J. Kiecolt-Glaser,
J. Bennett,
R. Andridge,
J. Peng,
C. Shapiro,
W. Malarkey,
...
C. Emery,
R. Layman,
E. Mrózek,
R. Glaser
|
8 |
2014 |
8
🐜
|
|
🐜
|
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
15 auth.
A. Schott,
M. Landis,
G. Dontu,
K. Griffith,
R. Layman,
I. Krop,
Lacey A. Paskett,
H. Wong,
L. Dobrolecki,
M. Lewis,
...
A. Froehlich,
Jaya Paranilam,
D. Hayes,
M. Wicha,
Jenny C. Chang
|
7 |
2013 |
7
🐜
|
|
🐜
|
Yoga and self‐reported cognitive problems in breast cancer survivors: a randomized controlled trial
12 auth.
H. Derry,
L. Jaremka,
J. Bennett,
J. Peng,
R. Andridge,
Charles Shapiro,
...
W. Malarkey,
C. Emery,
R. Layman,
E. Mrózek,
R. Glaser,
J. Kiecolt-Glaser
|
6 |
2015 |
6
🐜
|
|
🐜
|
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
17 auth.
M. Lustberg,
P. Balasubramanian,
B. Miller,
A. Garcia-Villa,
Clayton Deighan,
Yongqi Wu,
S. Carothers,
Michael Berger,
B. Ramaswamy,
Erin R. Macrae,
...
R. Wesolowski,
R. Layman,
E. Mrózek,
X. Pan,
T. Summers,
C. Shapiro,
J. Chalmers
|
6 |
2014 |
6
🐜
|
|
🐜
|
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
11 auth.
A. DeMichele,
M. Cristofanilli,
A. Brufsky,
Xianchen Liu,
J. Mardekian,
L. McRoy,
...
R. Layman,
B. Emir,
M. Torres,
H. Rugo,
R. Finn
|
6 |
2021 |
6
🐜
|
|
🐜
|
Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy
12 auth.
Kuei C. Lee,
B. Moffat,
A. Schott,
R. Layman,
S. Ellingworth,
Rebecca Juliar,
...
Amjad P. Khan,
M. Helvie,
C. Meyer,
T. Chenevert,
A. Rehemtulla,
B. Ross
|
6 |
2007 |
6
🐜
|
|
🐢
|
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
S. Vijayaraghavan,
S. Moulder,
K. Keyomarsi,
R. Layman
|
6 |
2018 |
6
🐢
|
|
🐜
|
CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).
12 auth.
W. Barry,
A. Moreno-Aspitia,
A. Lyss,
C. Cirrincione,
E. Mayer,
M. Naughton,
...
R. Layman,
L. Carey,
R. Somer,
E. Perez,
C. Hudis,
E. Winer
|
6 |
2012 |
6
🐜
|
|
🐜
|
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
12 auth.
H. Rugo,
A. Brufsky,
Xianchen Liu,
Benjamin Li,
L. McRoy,
Connie Chen,
...
R. Layman,
M. Cristofanilli,
M. Torres,
G. Curigliano,
R. Finn,
A. DeMichele
|
6 |
2022 |
6
🐜
|
|
🐜
|
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
18 auth.
R. Wesolowski,
Megan C. Duggan,
Andrew Stiff,
J. Markowitz,
P. Trikha,
Kala M. Levine,
L. Schoenfield,
M. Abdel-Rasoul,
R. Layman,
B. Ramaswamy,
...
Erin R. Macrae,
M. Lustberg,
R. Reinbolt,
E. Mrózek,
J. Byrd,
M. Caligiuri,
T. Mace,
W. Carson
|
5 |
2017 |
5
🐜
|
